QUOTIENT SCIENCES

We pioneered the integration of CRO/CDMO services with Translational Pharmaceutics®—a disruptive platform to enable greater efficiency in drug development. This unique approach integrates drug product manufacturing & clinical testing to reduce costs, improves decision-making and accelerate development timelines by up to 12 months.

Our comprehensive drug product (CDMO) services span a variety of dosage forms across early and late stage development, covering formulation development, clinical trial, and commercial manufacturing. We specialize in technologies for solubility enhancement, modified release, pediatric products, HPAPIs, and oral peptides. Our clinical pharmacology (CRO) services are focused on early phase, including Phase I studies from first-in-human (FIH), single and multiple ascending dose (SAD / MAD) to regulatory and exploratory clinical studies including human ADME, TQT, DDI, and bioavailability. For all projects, the customer experience is paramount, with expert project managers leading every aspect—from project start-up through to reporting.

With drug product development, manufacturing, and clinical testing facilities located in both the US and the UK, Quotient Sciences has worked with customers as a trusted CRDMO partner for over 35 years. Our approach to program design and delivery saves time in getting new therapies to market, without compromising quality and control of the product, data, and processes along the way.

With trusted scientific insight brought to every program, Quotient Sciences is a drug development & manufacturing accelerator helping clients bring molecules to cures, fast.